AMI Integration on Track: Several Product Groups Offer Growth
Opportunities VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today announced
financial results for the second quarter ended June 30, 2006. The
second quarter represents the first reporting period that includes
the results of operations from the business of American Medical
Instruments Holdings, Inc. (AMI), which was acquired by Angiotech
in March 2006. "Significantly, in our first combined quarter
following the AMI acquisition, we were able to deliver strong top
and bottom line results on record revenues and a highly diversified
product base," said Dr. William Hunter, President and CEO of
Angiotech. "We are pleased with the momentum behind the operational
and product integration activities, which are on or ahead of
schedule. Moving forward, we'll focus on key growth opportunities,
such as our aesthetics and biopsy product groups." HIGHLIGHTS FOR
THE QUARTER -------------------------- For complete financial
results, including Management's Discussion and Analysis and Interim
Financial Statements, please visit our website at
http://www.angiotech.com/. Financial Highlights - Total revenues
were $97.7 million and were principally derived from two operating
segments: Pharmaceutical Technologies (primarily generating
"Royalty Revenue" as indicated on the Consolidated Statements of
Income) and Medical Products (primarily generating "Product Sales"
as indicated in the Consolidated Statements of Income). - Royalty
revenues were $43.0 million, which included $41.3 million of
royalty revenue derived from sales by Boston Scientific Corporation
(BSC) of paclitaxel-eluting coronary stent systems, representing an
average blended royalty rate of 7.9 percent for US sales and 6.2
percent for other countries. - Royalty revenues received from BSC
were up approximately 5 percent relative to the first quarter based
on higher and stabilizing sales of paclitaxel-eluting stent
systems. - Product sales were $54.6 million, and were derived
primarily from the businesses obtained through the AMI acquisition.
- Investments were also made during the quarter to expand
opportunities in the aesthetics and wound closure areas, including
the completion of the acquisition of Quill Medical, Inc., and the
continued expansion of personnel, as well as sales and marketing
activities in both segments. - GAAP net income and net income per
share were $1.8 million and $0.02 respectively. - Adjusted net
income and adjusted net income per share were $17.5 million and
$0.20 respectively. Adjusted net income and net income per share
exclude certain litigation expenses incurred during the quarter,
which amounted to approximately ($0.02) per share. - Adjusted
EBITDA (earnings before interest, taxes, depreciation and
amortization, adjusted to exclude certain non-recurring and
non-cash items) during the quarter was $34.4 million. - Adjusted
operating income and adjusted operating income per share were $32.6
million and $0.38 respectively. Operational Highlights The main
focus of the past quarter has been the integration of the various
AMI businesses. The AMI businesses exhibited solid performance
during the quarter, with revenue at the upper end of the previously
articulated range described at Angiotech's Analyst and Investor Day
this past May. Operational and product interface activities are on
or ahead of schedule, and Angiotech has also begun to implement a
number of key opportunities for cost savings and operating
efficiencies across the acquired businesses. As part of these
integration activities, Angiotech has identified two product areas
with the most significant near-term growth potential: biopsy
products and aesthetic products. Also during the quarter, Angiotech
completed business development transactions with Genzyme
Corporation and Quill Medical, Inc. that align well with our
strategy of delivering proprietary medical device, pharmaceutical,
and combination drug-device products to surgeons and
interventionists. We believe these transactions establish the
foundation for future product revenue and new product development
in the areas of oncology, aesthetic surgery and general surgical
wound closure. Quill Medical Acquisition - Access to Aesthetics and
Wound Closure Markets On June 28, 2006, Angiotech announced the
completion of its acquisition of privately held Quill Medical, Inc.
- including all of its technology and intellectual property - for
$40 million in cash plus certain future contingent payments based
on milestones and incremental product revenue increases. This
acquisition allows Angiotech to fully capture the value of the
Contour Threads(TM) self-anchoring suture franchise in the
aesthetics market. In addition, Angiotech now has the rights to
market, manufacture and sell self-anchoring suture product lines
using Quill's technology into all medical markets, including the
suture-based wound closure market. Aesthetics Products - Momentum
in the Contour Threads(TM) Aesthetics Franchise Angiotech expects
the aesthetics product lines acquired through AMI to be a key
growth driver in coming quarters and during 2007. In the second
quarter, Angiotech continued to invest in its proprietary Contour
Threads product line used for minimally invasive aesthetic
surgeries by establishing distribution and independent sales
agreements in various geographies; holding physician training
courses; hiring clinical specialists (which are a key component of
physician training and support); and starting the process of
clinical trial initiations for new indications such as breast lift
and nipple repositioning procedures. Biopsy Products The biopsy
product lines acquired through AMI were key revenue contributors
during the quarter. In addition, Angiotech is developing one of its
first synergy products, a biopsy needle coated with our proprietary
ECHO-COAT(R) biomaterial, that we believe will strengthen our
position and growth potential in this important product segment. An
uncoated needle cannot be seen in an ultrasound. The ECHO-COAT
ultrasound imaging biomaterial is a patented technology that
creates a microporous structure that traps air on the surface of a
device. Since air is an efficient reflector of sound waves, the
trapped air bubbles on the surface reflect ultrasound in all
directions and can enable the coated biopsy needle to be visible at
virtually any angle of insertion under ultrasound imaging. Tumor
Resection Treatments - Genzyme Collaboration In May 2006, Angiotech
jointly announced with Genzyme a major strategic collaboration
agreement designed to identify, develop and commercialize
innovative therapies for cancer patients undergoing the surgical
removal of tumors. Specifically, the two companies will collaborate
to create novel, localized treatments that target the prevention of
tumor re-growth after surgery through the direct application of a
combined biomaterial/anti-cancer therapeutic at the site where the
tumor is removed. Both companies believe that these products will
be useful in treating inoperable tumors, reducing local tumor
side-effects, and improving surgical outcomes while complementing
existing systemic therapies. Clinical Update Angiotech is currently
conducting human clinical trials with respect to two key product
candidates. For more information on the status of selected clinical
programs either being conducted by Angiotech or its corporate
partners, please see our Management's Discussion and Analysis that
can be found on our website or on http://www.sedar.com/. Vascular
Wrap(TM) Program Angiotech's most advanced product candidate is the
Vascular Wrap(TM) paclitaxel-eluting mesh surgical implant
("Vascular Wrap mesh"), a biodegradable, synthetic mesh surgical
implant loaded with paclitaxel. The Vascular Wrap mesh is applied
to the outside of a vessel wall by a vascular surgeon in order to
prevent or reduce restenosis associated with vascular surgical
procedures. Angiotech currently is conducting a 109 patient, fully
enrolled European clinical trial, which is a first-in-man study
designed to evaluate the safety of the Vascular Wrap mesh when used
in conjunction with peripheral vascular bypass surgery in the limbs
using a synthetic vascular graft. We expect to provide additional
data from this study, and to determine if the data will support the
filing of a CE mark in order to market the Vascular Wrap mesh in
the European Union, in the second half of 2006. In addition,
Angiotech announced plans last November to initiate the PREVAIL
(Paclitaxel Releasing Extra-Vascular Anastomosis Implant &
Lifespan Graft) clinical trial in 2006 in the United States.
PREVAIL will be designed to assess the safety and efficacy of the
Vascular Wrap as implanted in combination with Angiotech's recently
acquired synthetic vascular graft product line in hemodialysis
patients with renal disease who receive arteriovenous ("AV") access
implants. Angiotech is currently in discussions with the United
States Food and Drug Administration ("FDA") to finalize the design
and timing of the PREVAIL study, with an expected start date for
the study in the second half of 2006. CVC Program Angiotech's
proprietary, 5-fluorouracil-eluting, anti-microbial central venous
catheter (CVC) used to prevent line infections in critical care
patients is currently undergoing a human clinical trial in the
United States. CVC's are usually inserted into critically ill
patients for extended periods of time to administer fluids, drugs
and nutrition, as well as to facilitate frequent blood draws. In
January 2006, Angiotech announced the initiation of a human
clinical study designed to examine the safety and efficacy of the
CVC. The study is a randomized, single blind, 850 patient, 20
center study. There were 168 patients enrolled in the study as of
the end of the second quarter. If the CVC study results are
favourable, we intend to request a 510(k) clearance from the FDA to
market and sell the CVC in the United States, potentially in the
first half of 2007. Financial Information and Certain Non-GAAP
Financial Measures
------------------------------------------------------------- This
press release contains the condensed financial statements derived
from the unaudited consolidated interim financial statements for
the three and six month periods ended June 30, 2006 and the audited
consolidated financial statements for the year ended December 31,
2005. For a copy of our full financial results for the second
quarter, including Management's Discussion and Analysis and Interim
Financial Statements, please visit our website at
http://www.angiotech.com/. The following discussion and analysis of
results from our operations excludes the financial results from our
Dutch subsidiaries (MCTec Holdings BV and MCTec BV) and NeuColl,
Inc. which are reported as discontinued operations. All discussions
and analyses pertain to continuing operations only, unless
otherwise noted. Due to the timing of the acquisition of AMI in
relation to the March 31, 2006 reporting period, the net earnings
of AMI for the period from March 23 to March 31, 2006 have been
included in the net earnings for the three months ended June 30,
2006 as the net earnings for this period were not considered
material. Since AMI was acquired on March 23, 2006, the comparative
three and six month periods ended June 30, 2005 do not include the
results of AMI operations. Amounts, unless specified otherwise, are
expressed in U.S. dollars. Financial results are reported under
United States generally accepted accounting principles ("U.S.
GAAP") unless otherwise noted. All per share amounts are stated on
a diluted basis unless otherwise noted. Certain financial results
presented in this press release include non-GAAP measures that
exclude certain items. Adjusted net income from continuing
operations and adjusted earnings before interest, taxes,
depreciation and amortization ("adjusted EBITDA") exclude
acquisition related amortization charges, acquired in-process
research and development relating to license agreements and
acquisitions, stock based compensation expense, foreign exchange
gains or losses relating to translation of foreign currency cash
and investment balances and other non-recurring items. Adjusted net
income from continuing operations and adjusted EBITDA also do not
include litigation expenses related to defending intellectual
property claims. Adjusted net income from continuing operations and
adjusted EBITDA do not have any standardized meaning prescribed by
GAAP and therefore may not be comparable to similar measures
presented by other issuers. Management uses these non-GAAP or
adjusted operating measures to establish operational goals, and
believes that these measures may assist investors in analyzing the
underlying trends in our business over time. Investors should
consider these non-GAAP measures in addition to, not as a
substitute for, or as superior to, financial reporting measures
prepared in accordance with GAAP. We have provided a reconciliation
of adjusted net income from continuing operations to net income
according to GAAP, and have provided a definition and a
reconciliation of net income to adjusted EBITDA, in the attached
tables. Conference Call Information --------------------------- A
conference call to discuss these financial results and other
quarterly highlights will be held today, Thursday August 3, 2006 at
8 AM PDT (11 AM EDT). Dial-in information: North America (toll
free): 1-866-314-4483 International: 1-617-213-8049 Enter passcode:
78153412 A replay archive of the conference call will be available
until August 10, 2006 by calling 1-888-286-8010 (in North America)
or 1-617-801-6888 (International) and entering Access Code
57578072. A live webcast will be available to all interested
parties through the Investors section of Angiotech's website:
http://www.angiotech.com/. Forward-Looking Statements
-------------------------- Statements contained in this report that
are not based on historical fact, including without limitation
statements containing the words "believes," "may," "plans," "will,"
"estimate," "continue," "anticipates," "intends," "expects" and
similar expressions, constitute "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable
securities legislation. Forward-looking statements may involve, but
are not limited to, comments with respect to our objectives and
priorities for 2006 and beyond, our strategies or future actions,
our targets, expectations for our financial condition and the
results of, or outlook for, our operations, research development
and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors are taken into account as part of our
assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate;
technological changes that impact our existing products or our
ability to develop and commercialize future products; competition;
changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental
regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in
drug discovery, clinical and other development processes; failure
to obtain patent protection for discoveries; loss of patent
protection resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; dependence upon, and relationships
with strategic alliance partners to develop and commercialize
products and services based on our work; our ability to obtain
rights to technology from licensors; liability for patent claims
and other claims asserted against us; the requirement for
substantial funding to conduct research and development and to
expand commercialization activities or consummate acquisitions;
other factors referenced in our annual information form and other
filings with the applicable Canadian securities regulatory
authorities or the Securities and Exchange Commission; and any
other factors that may affect performance. In addition, the actual
results expressed or implied by certain forward-looking statements
contained in this report may be affected by our acquisition of AMI,
which we completed on March 23, 2006 and the related transactions.
There can be no assurance that (i) the operational and other
synergies, (ii) the projected or expected financial or commercial
benefits, or (iii) the potential for future product sales or
product development activities all related to the acquisition of
AMI will be realized in the amounts or times contemplated. In
addition, the forward-looking statements contained in this report
are based upon a number of material assumptions, all of which we
believe are reasonable, including, but not limited to assumptions
related to the following: general economic and business conditions
remaining stable; our ability to integrate AMI into our operations,
including our ability to apply our various technologies to AMI's
medical devices and subsequently commercialize those products; our
ability to realize operational and other synergies related to our
acquisition of AMI in the times and amounts contemplated; our
ability to realize projected or expected financial or commercial
benefits from our acquisition of AMI; our future product and drug
development activities and clinical development processes being
realized in the times and for the amounts contemplated; ability to
obtain regulatory approval for products or therapies identified;
availability of funding and resources for research and development;
performance by our collaboration partners of their research and
development commitments; and marketability of any products
successfully developed by Angiotech and its partners. In addition,
our business is subject to certain operating risks that may cause
the actual results expressed or implied by the forward-looking
statements in this report to differ materially from our actual
results. These operating risks include: our ability to successfully
complete preclinical and clinical development of our products; the
ability to obtain and enforce timely patent and other intellectual
property protection for our technology and products; decisions, and
the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the ability to
complete and maintain corporate alliances relating to the
development and commercialization of our technology and products;
market acceptance of our technology and products; the competitive
environment and impact of technological change; the continued
availability of capital to finance our activities; our ability to
integrate into our business the operations of AMI; and our ability
to achieve the operational and other synergies and the other
commercial or financial benefits expected as a result of the
acquisition of AMI. Given these uncertainties, assumptions and risk
factors, readers are cautioned not to place undue reliance on such
forward-looking statements. We disclaim any obligation to update
any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this report to reflect future results, events or developments.
About Angiotech Pharmaceuticals Angiotech Pharmaceuticals, Inc. is
a global specialty pharmaceutical and medical device company with
14 facilities in 6 countries and over 1,500 dedicated employees.
Angiotech discovers, develops and markets innovative treatment
solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find
out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. ANGIOTECH PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (in
thousands of U.S.$, except Three months ended share and per share
data) June 30, 2006
-------------------------------------------------------------------------
Reported Adjustments Adjusted REVENUE Royalty revenue 42,980 42,980
Product sales, net 54,631 54,631 License fees 73 (73)(a) -
-------------------------------------------------------------------------
97,684 (73) 97,611
-------------------------------------------------------------------------
EXPENSES License and royalty fees 6,050 6,050 Cost of products sold
26,517 26,517 Research and development 11,833 (773)(b) 11,060
Selling, general and administrative 24,441 (1,007)(b) 20,632
(2,802)(d) Depreciation and amortization 10,539 (9,758)(e) 781
-------------------------------------------------------------------------
79,380 (14,340) 65,040
-------------------------------------------------------------------------
Operating income 18,304 14,267 32,571
-------------------------------------------------------------------------
Other income (expenses): Foreign exchange gain (loss) 2,135
(2,135)(f) - Investment and other income 1,813 (685)(g) 1,128
Interest expense on long-term debt (11,297) 675(h) (10,622) Gain on
redemption of investments 1,064 (1,064)(i) -
-------------------------------------------------------------------------
(6,285) (3,209) (9,494)
-------------------------------------------------------------------------
Income from continuing operations before income taxes 12,019 11,058
23,077 Income tax expense 9,708 (4,088)(j) 5,620
-------------------------------------------------------------------------
Net income from continuing operations 2,311 15,146 17,457
-------------------------------------------------------------------------
Net loss from discontinued operations, net of income taxes (484)
484 -
-------------------------------------------------------------------------
Net income for the period 1,827 15,630 17,457
-------------------------------------------------------------------------
Basic net income per common share from continuing operations 0.03
0.21 Diluted net income per common share from continuing operations
0.03 0.20
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average shares outstanding (000's) - basic 84,651 84,651
Weighted average shares outstanding (000's) - diluted 85,710 85,710
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(in thousands of U.S.$, except Three months ended share and per
share data) June 30, 2005
-------------------------------------------------------------------------
Reported Adjustments Adjusted REVENUE Royalty revenue 50,704 50,704
Product sales, net 959 959 License fees 568 (568)(a) -
-------------------------------------------------------------------------
52,231 (568) 51,663
-------------------------------------------------------------------------
EXPENSES License and royalty fees 6,718 (2)(a) 6,716 Cost of
products sold 1,037 1,037 Research and development 7,669 (489)(b)
7,027 (153)(c) Selling, general and administrative 12,431 (795)(b)
4,307 (406)(c) (6,923)(d) Depreciation and amortization 2,244
(1,667)(e) 577
-------------------------------------------------------------------------
30,099 (10,435) 19,664
-------------------------------------------------------------------------
Operating income 22,132 9,867 31,999
-------------------------------------------------------------------------
Other income (expenses): Foreign exchange gain (loss) (609) 609(f)
- Investment and other income 2,523 2,523 Interest expense on
long-term debt - - Gain on redemption of investments - -
-------------------------------------------------------------------------
1,914 609 2,523
-------------------------------------------------------------------------
Income from continuing operations before income taxes 24,046 10,476
34,522 Income tax expense 8,481 4,953(k) 13,434
-------------------------------------------------------------------------
Net income from continuing operations 15,565 5,523 21,088
-------------------------------------------------------------------------
Net loss from discontinued operations, net of income taxes (245)
245 -
-------------------------------------------------------------------------
Net income for the period 15,320 5,768 21,088
-------------------------------------------------------------------------
Basic net income per common share from continuing operations 0.19
0.25 Diluted net income per common share from continuing operations
0.18 0.25
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average shares outstanding (000's) - basic 84,116 84,116
Weighted average shares outstanding (000's) - diluted 84,153 84,153
-------------------------------------------------------------------------
-------------------------------------------------------------------------
a. Non-recurring license fee revenue relating to license agreements
and other non-recurring license fee revenue, net of license fees
due to licensors. (In 2005, license agreement with Broncus
Technologies, Inc. ($0.5 million)). b. Stock-based compensation
expense. c. Termination costs relating to consolidation activities
at Palo Alto facility. d. Litigation expenses relating to defending
intellectual property claims. e. Amortization of acquisition
related intangible assets and medical technologies. f. Foreign
exchange fluctuations on foreign currency net monetary assets. g.
Gain on sale of Palo Alto building - assets held for sale h.
Amortization of deferred financing costs. i. Gain on redemption of
long-term, available-for-sale securities and Palo Alto building. j.
Non-recurring Quebec retroactive tax adjustment ($8.7 million) and
tax effects of adjustments a. through j. ($4.6 million). k.
Non-recurring tax benefit of additional investment tax credits
approved by the Canadian taxation authorities ($1.5 million) and
tax effects of adjustments b. through g. ($3.5 million). ANGIOTECH
PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited) (in thousands of U.S.$, except Six months ended share
and per share data) June 30, 2006
-------------------------------------------------------------------------
Reported Adjustments Adjusted REVENUE Royalty revenue 84,070 84,070
Product sales, net 55,433 55,433 License fees 126 (126)(a) -
-------------------------------------------------------------------------
139,629 (126) 139,503
-------------------------------------------------------------------------
EXPENSES License and royalty fees 12,563 12,563 Cost of products
sold 27,151 27,151 Research and development 21,321 (1,227)(b)
20,094 Selling, general and administrative 34,583 (1,654)(b) 26,599
(6,330)(d) Depreciation and amortization 12,705 (11,321)(e) 1,384
In-process research and development 1,042 (1,042)(f) -
-------------------------------------------------------------------------
109,365 (21,574) 87,791
-------------------------------------------------------------------------
Operating income 30,264 21,448 51,712
-------------------------------------------------------------------------
Other income (expenses): Foreign exchange gain (loss) 2,306
(2,306)(g) - Investment and other income 4,517 (685)(h) 3,832
Interest expense on long-term debt (12,286) 675(i) (11,611) Loss on
redemption of investments (413) 413(j) -
-------------------------------------------------------------------------
(5,876) (1,903) (7,779)
-------------------------------------------------------------------------
Income from continuing operations before income taxes 24,388 19,545
43,933 Income tax expense 14,097 (2,455)(k) 11,642
-------------------------------------------------------------------------
Net income from continuing operations 10,291 22,000 32,291
-------------------------------------------------------------------------
Net loss from discontinued operations, net of income taxes (929)
929 -
-------------------------------------------------------------------------
Net income for the period 9,362 22,929 32,291
-------------------------------------------------------------------------
Basic net income per common share from continuing operations 0.12
0.38 Diluted net income per common share from continuing operations
0.12 0.38
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average shares outstanding (000's) - basic 84,593 84,593
Weighted average shares outstanding (000's) - diluted 85,777 85,777
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(in thousands of U.S.$, except Six months ended share and per share
data) June 30, 2005
-------------------------------------------------------------------------
Reported Adjustments Adjusted REVENUE Royalty revenue 101,978
101,978 Product sales, net 2,017 2,017 License fees 3,916
(3,916)(a) -
-------------------------------------------------------------------------
107,911 (3,916) 103,995
-------------------------------------------------------------------------
EXPENSES License and royalty fees 14,717 (427)(a) 14,290 Cost of
products sold 1,982 1,982 Research and development 15,167
(1,002)(b) 13,112 (1,053)(c) Selling, general and administrative
18,979 (1,573)(b) 8,403 (673)(c) (8,330)(d) Depreciation and
amortization 4,503 (3,230)(e) 1,273 In-process research and
development 1,000 (1,000)(f) -
-------------------------------------------------------------------------
56,348 (17,288) 43,761
-------------------------------------------------------------------------
Operating income 51,563 13,372 60,234
-------------------------------------------------------------------------
Other income (expenses): Foreign exchange gain (loss) (1,037)
1,037(g) - Investment and other income 4,352 4,352 Interest expense
on long-term debt - - Loss on redemption of investments - -
-------------------------------------------------------------------------
3,315 1,037 4,352
-------------------------------------------------------------------------
Income from continuing operations before income taxes 54,878 14,409
69,287 Income tax expense 20,079 6,606(l) 26,685
-------------------------------------------------------------------------
Net income from continuing operations 34,799 7,803 42,602
-------------------------------------------------------------------------
Net loss from discontinued operations, net of income taxes (651)
651 -
-------------------------------------------------------------------------
Net income for the period 34,148 8,454 42,602
-------------------------------------------------------------------------
Basic net income per common share from continuing operations 0.42
0.51 Diluted net income per common share from continuing operations
0.41 0.51
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average shares outstanding (000's) - basic 84,083 84,083
Weighted average shares outstanding (000's) - diluted 84,120 84,120
-------------------------------------------------------------------------
-------------------------------------------------------------------------
a. Non-recurring license fee revenue relating to license agreement
and other license fee revenue, net of license fees due to
licensors. (In 2005, license agreements with CABG Medical, Inc.
($3.3 million) and Broncus Technologies, Inc. ($0.5 million)). b.
Stock-based compensation expense. c. Termination costs relating to
consolidation activities at Palo Alto facility. d. Litigation
expenses relating to defending intellectual property claims. e.
Amortization of acquisition related intangible assets and medical
technologies. f. In-process research and development expense,
relating primarily to $1.0 million payment due under license
agreement with Poly-Med, Inc. g. Foreign exchange fluctuations on
foreign currency net monetary assets. h. Gain on sale of Palo Alto
building - assets held for sale. i. Amortization of deferred
financing costs. j. Loss on redemption of investments. k.
Non-recurring Quebec retroactive tax adjustment ($8.7 million) and
tax effects of adjustments a. through k. ($6.2 million). l.
Non-recurring tax benefit of additional investment tax credits
approved by the Canadian taxation authorities ($1.5 million) and
tax effects of adjustments b. through h. ($5.1 million). ANGIOTECH
PHARMACEUTICALS, INC. CALCULATION OF ADJUSTED EBITDA (Unaudited)
Three months ended Six months ended June 30, June 30, (in thousands
of U.S.$) 2006 2005 2006 2005
-------------------------------------------------------------------------
Net income on a GAAP basis 1,827 15,320 9,362 34,148 Interest
expense on long-term debt 11,297 - 12,286 - Income tax expense
9,578 8,315 13,967 19,744 Depreciation and amortization 11,591
2,836 13,838 5,690
-------------------------------------------------------------------------
EBITDA 34,293 26,471 49,453 59,582
-------------------------------------------------------------------------
Adjustments: Net (income)/loss from discontinued operations,
excluding depreciation, amortization and income tax expense
included above 568 (86) 968 (12) In-process research and
development - - 1,042 1,000 Non-recurring revenue, net of license
fees (73) (566) (126) (3,489) Stock-based compensation 1,780 1,284
2,881 3,263 Palo Alto consolidation expenses - 559 - 1,726
Litigation expenses 2,802 6,923 6,330 8,330 Foreign exchange (gain)
loss (2,135) 609 (2,306) 1,037 Investment and other income (1,128)
(2,523) (3,832) (4,352) Gain on sale of Palo Alto building (685) -
(685) - (Gain) loss on redemption of investments (1,064) - 413 -
-------------------------------------------------------------------------
Adjusted EBITDA 34,358 32,671 54,138 67,085
-------------------------------------------------------------------------
-------------------------------------------------------------------------
ANGIOTECH PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE
SHEETS (Unaudited) As at June 30, December 31, (in thousands of
U.S.$) 2006 2005
-------------------------------------------------------------------------
ASSETS Cash and short-term investments 73,526 195,442 Accounts
receivable 27,696 3,377 Inventories 30,606 786 Other current assets
9,312 9,267
-------------------------------------------------------------------------
Total current assets 141,140 208,872
-------------------------------------------------------------------------
Long-term investments 52,312 170,578 Property and equipment, net
66,773 11,042 Intangible assets, net 275,069 45,447 Goodwill
644,999 46,071 Deferred income taxes 4,571 11,350 Deferred
financing costs 17,558 - Other assets 2,191 1,334
-------------------------------------------------------------------------
1,204,613 494,694
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities 66,452
27,555 Long-term debt 569,340 - Deferred income taxes 82,230 -
Other long-term liabilities 4,249 4,459 Stockholders' equity
482,342 462,680
-------------------------------------------------------------------------
1,204,613 494,694
-------------------------------------------------------------------------
-------------------------------------------------------------------------
CONTACT: Analysts and Institutional Investors: Janet Craig, VP,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., ; Media and Retail Investors: Jodi Regts,
Manager, Corporate Communications, Angiotech Pharmaceuticals, Inc.,
, (604) 221-7930; Business and Financial Media: Judith Sylk-Siegel,
Rx Communications Group, LLC, (917) 322-2164 DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Analysts and Institutional
Investors: Janet Craig, VP, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., ; Media and Retail
Investors: Jodi Regts, Manager, Corporate Communications, Angiotech
Pharmaceuticals, Inc., , (604) 221-7930; Business and Financial
Media: Judith Sylk-Siegel, Rx Communications Group, LLC, (917)
322-2164
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Okt 2023 bis Okt 2024